The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Polymorphisms of the aromatase gene (CYP19A1) and benefit of aromatase inhibitors (AIs) in metastatic breast cancer (mBC) patients.
M. Arnedos
No relevant relationships to disclose
R. Ferraldeschi
No relevant relationships to disclose
R. A'Hern
No relevant relationships to disclose
K. Hadfield
No relevant relationships to disclose
S. Roberts
No relevant relationships to disclose
S. Drury
No relevant relationships to disclose
A. Howell
No relevant relationships to disclose
D. G. Evans
No relevant relationships to disclose
A. M. Wardley
No relevant relationships to disclose
I. E. Smith
No relevant relationships to disclose
W. G. Newman
No relevant relationships to disclose
M. Dowsett
Consultant or Advisory Role - AstraZeneca; Novartis
Honoraria - AstraZeneca; Novartis
Research Funding - AstraZeneca; Novartis
Expert Testimony - AstraZeneca